NASDAQ:ATRS - Nasdaq - US0366421065 - Common Stock
ATRS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. The financial health of ATRS is average, but there are quite some concerns on its profitability. ATRS shows excellent growth, but is valued quite expensive already.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Altman-Z | 8.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.59
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 | ||
P/S | 5.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.43 | ||
P/tB | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 | ||
Altman-Z | 8.15 |